One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritisTwo trials for ...

Frailty and functional dependency affect treatment satisfaction and may require tailored care for older adults with psoriasis ...

Study authors examined the use of artificial intelligence in machine learning models for the assessment of psoriasis severity, as well as identified future research needs.

A very large percentage of all of these patient segments are currently ... of ZORYVE foam to help patients with scalp and ...

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

Discover a recent study from 12 hospitals across China that has shed new light on personalised care for plaque psoriasis.

Psoriasis is a chronic autoimmune disorder that causes raised areas of dry, itchy, scaly skin. It is not contagious but can cause unsightly and even painful lesions covering large parts of the body in ...

The patient's Psoriasis Area and Severity Index (PASI) score improved from 15 to 100 without experiencing any adverse effects of significance. A rare case of psoriasis vulgaris and myelofibrosis (MF) ...

This deal represents a true win-win outcome for Organon and Roivant in our mutual goal to address patient needs and is emblematic of Roivant’s ability to form non-traditional, value-enhancing ...